Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
10.44
+0.04 (0.38%)
At close: Apr 28, 2026, 4:00 PM EDT
10.44
0.00 (0.00%)
After-hours: Apr 28, 2026, 5:12 PM EDT
Telix Pharmaceuticals Employees
As of December 31, 2025, Telix Pharmaceuticals had 1,184 total employees, including 1,120 full-time and 64 part-time employees. The number of employees increased by 950 or 405.98% compared to the previous year.
Employees
1,184
Change
950
Growth
405.98%
Revenue / Employee
$678,880
Profits / Employee
-$6,018
Market Cap
3.59B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1,184 | 950 | 405.98% |
| Dec 31, 2022 | 234 | 76 | 48.10% |
| Dec 31, 2021 | 158 | 149 | 1,655.56% |
| Dec 31, 2017 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ACADIA Pharmaceuticals | 798 |
| Crinetics Pharmaceuticals | 594 |
| Denali Therapeutics | 503 |
| Travere Therapeutics | 497 |
| Catalyst Pharmaceuticals | 182 |
| Edgewise Therapeutics | 146 |
| Tango Therapeutics | 137 |
| NewAmsterdam Pharma Company | 100 |
TLX News
- 23 hours ago - Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach - GlobeNewsWire
- 7 days ago - ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026 - GlobeNewsWire
- 13 days ago - Telix Pharma Doses First Patient In Phase 3 IPAX BrIGHT Trial Of TLX101-Tx; Prices $600 Mln Bonds - Nasdaq
- 13 days ago - Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma - GlobeNewsWire
- 14 days ago - Fundies feast on Telix Pharmaceuticals block amid $US550m convertible - The Australian Financial Review
- 15 days ago - Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs - Benzinga
- 15 days ago - Regeneron (REGN) Partners with Telix Pharmaceuticals - GuruFocus
- 15 days ago - Regeneron (REGN) Partners with Telix Pharmaceuticals for Innovative Radiopharmaceuticals - GuruFocus